{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T07:29:13Z","timestamp":1790666953206,"version":"4.1.0"},"reference-count":178,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2018,12,4]],"date-time":"2018-12-04T00:00:00Z","timestamp":1543881600000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004097","name":"Fondation ARC pour la Recherche sur le Cancer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004097","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100006331","name":"Cancerop\u00f4le PACA","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100006331","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"DOI":"10.3389\/fonc.2018.00556","type":"journal-article","created":{"date-parts":[[2018,12,4]],"date-time":"2018-12-04T06:07:00Z","timestamp":1543903620000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":81,"title":["Metabolic Reprogramming of Non-Hodgkin's B-Cell Lymphomas and Potential Therapeutic Strategies"],"prefix":"10.3389","volume":"8","author":[{"given":"Jean-Ehrland","family":"Ricci","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johanna","family":"Chiche","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2018,12,4]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"341","DOI":"10.20892\/j.issn.2095-3941.2017.0090","article-title":"The ascent of immune checkpoint inhibitors: is the understudy ready for a leading role?","volume":"14","author":"Cummings","year":"2017","journal-title":"Cancer Biol Med"},{"key":"B2","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/j.it.2014.11.005","article-title":"Regulation of T cells by mTOR: the known knowns and the known unknowns","volume":"36","author":"Pollizzi","year":"2015","journal-title":"Trends Immunol"},{"key":"B3","doi-asserted-by":"publisher","first-page":"2250","DOI":"10.4049\/jimmunol.1600492","article-title":"Conditional disruption of raptor reveals an essential role for mTORC1 in B cell development, survival, and metabolism","volume":"197","author":"Iwata","year":"2016","journal-title":"J Immunol."},{"key":"B4","doi-asserted-by":"publisher","first-page":"1045","DOI":"10.1016\/j.immuni.2017.06.005","article-title":"Germinal center selection and affinity maturation require dynamic regulation of mTORC1 kinase","volume":"46","author":"Ersching","year":"2017","journal-title":"Immunity"},{"key":"B5","doi-asserted-by":"crossref","first-page":"3909","DOI":"10.1182\/blood.V89.11.3909","article-title":"The Non-Hodgkin's Lymphoma Classification Project","volume":"89","author":"A","year":"1997","journal-title":"Blood"},{"key":"B6","doi-asserted-by":"publisher","first-page":"7359","DOI":"10.1038\/sj.onc.1206939","article-title":"Rituximab (monoclonal anti-CD20 antibody): mechanisms of action and resistance","volume":"22","author":"Smith","year":"2003","journal-title":"Oncogene"},{"key":"B7","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1038\/nrc3579","article-title":"Disrupting proton dynamics and energy metabolism for cancer therapy","volume":"13","author":"Parks","year":"2013","journal-title":"Nat Rev Cancer"},{"key":"B8","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1038\/nrc3483","article-title":"Cancer metabolism: fatty acid oxidation in the limelight","volume":"13","author":"Carracedo","year":"2013","journal-title":"Nat Rev Cancer"},{"key":"B9","doi-asserted-by":"publisher","first-page":"2531","DOI":"10.1016\/j.bbamcr.2015.12.017","article-title":"Glutamine transporters in mammalian cells and their functions in physiology and cancer","volume":"1863","author":"Bhutia","year":"2016","journal-title":"Biochim Biophys Acta"},{"key":"B10","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1016\/j.ccr.2013.08.020","article-title":"Glutamine sensitivity analysis identifies the xCT antiporter as a common triple-negative breast tumor therapeutic target","volume":"24","author":"Timmerman","year":"2013","journal-title":"Cancer Cell"},{"key":"B11","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1016\/j.cmet.2016.01.007","article-title":"Environment impacts the metabolic dependencies of ras-driven non-small cell lung cancer","volume":"23","author":"Davidson","year":"2016","journal-title":"Cell Metab"},{"key":"B12","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1172\/JCI72873","article-title":"Pyruvate carboxylase is critical for non-small-cell lung cancer proliferation","volume":"125","author":"Sellers","year":"2015","journal-title":"J Clin Invest"},{"key":"B13","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1016\/j.cmet.2012.10.010","article-title":"Analysis of tumor metabolism reveals mitochondrial glucose oxidation in genetically diverse human glioblastomas in the mouse brain in vivo","volume":"15","author":"Marin-Valencia","year":"2012","journal-title":"Cell Metab"},{"key":"B14","doi-asserted-by":"publisher","first-page":"1556","DOI":"10.1038\/ncb3272","article-title":"Glutamine synthetase activity fuels nucleotide biosynthesis and supports growth of glutamine-restricted glioblastoma","volume":"17","author":"Tardito","year":"2015","journal-title":"Nat Cell Biol"},{"key":"B15","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1038\/nature12138","article-title":"Macropinocytosis of protein is an amino acid supply route in Ras-transformed cells","volume":"497","author":"Commisso","year":"2013","journal-title":"Nature"},{"key":"B16","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1158\/0008-5472.CAN-14-2211","article-title":"Human pancreatic cancer tumors are nutrient poor and tumor cells actively scavenge extracellular protein","volume":"75","author":"Kamphorst","year":"2015","journal-title":"Cancer Res"},{"key":"B17","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1038\/nm.4256","article-title":"Direct evidence for cancer-cell-autonomous extracellular protein catabolism in pancreatic tumors","volume":"23","author":"Davidson","year":"2016","journal-title":"Nat Med"},{"key":"B18","doi-asserted-by":"publisher","first-page":"274ra17","DOI":"10.1126\/scitranslmed.aaa1009","article-title":"Glutamine-based PET imaging facilitates enhanced metabolic evaluation of gliomas in vivo","volume":"7","author":"Venneti","year":"2015","journal-title":"Sci Transl Med"},{"key":"B19","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1016\/j.cmet.2011.12.009","article-title":"Glucose-independent glutamine metabolism via TCA cycling for proliferation and survival in B cells","volume":"15","author":"Le","year":"2012","journal-title":"Cell Metab"},{"key":"B20","doi-asserted-by":"publisher","first-page":"e1600200","DOI":"10.1126\/sciadv.1600200","article-title":"Fundamentals of cancer metabolism","volume":"2","author":"DeBerardinis","year":"2016","journal-title":"Sci Adv"},{"key":"B21","doi-asserted-by":"publisher","first-page":"1229","DOI":"10.1016\/j.cell.2015.08.016","article-title":"Metabolic competition in the tumor microenvironment is a driver of cancer progression","volume":"162","author":"Chang","year":"2015","journal-title":"Cell"},{"key":"B22","doi-asserted-by":"publisher","first-page":"6659","DOI":"10.1074\/jbc.RA117.000470","article-title":"Adaptive remodeling of skeletal muscle energy metabolism in high-altitude hypoxia: lessons from altitudeomics","volume":"293","author":"Chicco","year":"2018","journal-title":"J Biol Chem"},{"key":"B23","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1016\/j.ceb.2007.02.003","article-title":"Hypoxia signalling controls metabolic demand","volume":"19","author":"Brahimi-Horn","year":"2007","journal-title":"Curr Opin Cell Biol"},{"key":"B24","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1126\/science.124.3215.269","article-title":"On respiratory impairment in cancer cells","volume":"124","author":"Warburg","year":"1956","journal-title":"Science"},{"key":"B25","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1038\/nrc3038","article-title":"Otto Warburg's contributions to current concepts of cancer metabolism","volume":"11","author":"Koppenol","year":"2011","journal-title":"Nat Rev Cancer"},{"key":"B26","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.1126\/science.1160809","article-title":"Understanding the warburg effect: the metabolic requirements of cell proliferation","volume":"324","author":"Vander Heiden","year":"2009","journal-title":"Science"},{"key":"B27","doi-asserted-by":"publisher","first-page":"1239","DOI":"10.1016\/j.cell.2013.05.016","article-title":"Posttranscriptional control of T cell effector function by aerobic glycolysis","volume":"153","author":"Chang","year":"2013","journal-title":"Cell"},{"key":"B28","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1146\/annurev-immunol-042617-053019","article-title":"Unraveling the complex interplay between T cell metabolism and function","volume":"36","author":"Geltink","year":"2018","journal-title":"Annu Rev Immunol"},{"key":"B29","doi-asserted-by":"publisher","first-page":"1367","DOI":"10.1084\/jem.20110278","article-title":"HIF1alpha-dependent glycolytic pathway orchestrates a metabolic checkpoint for the differentiation of TH17 and Treg cells","volume":"208","author":"Shi","year":"2011","journal-title":"J Exp Med"},{"key":"B30","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1111\/j.1600-065X.2012.01150.x","article-title":"Metabolic switching and fuel choice during T-cell differentiation and memory development","volume":"249","author":"van der Windt","year":"2012","journal-title":"Immunol Rev"},{"key":"B31","doi-asserted-by":"publisher","first-page":"3930","DOI":"10.1172\/JCI36843","article-title":"Targeting lactate-fueled respiration selectively kills hypoxic tumor cells in mice","volume":"118","author":"Sonveaux","year":"2008","journal-title":"J Clin Invest"},{"key":"B32","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1016\/j.cmet.2016.08.011","article-title":"LDHA-associated lactic acid production blunts tumor immunosurveillance by T and NK Cells","volume":"24","author":"Brand","year":"2016","journal-title":"Cell Metab"},{"key":"B33","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.cmet.2007.10.002","article-title":"The biology of cancer: metabolic reprogramming fuels cell growth and proliferation","volume":"7","author":"DeBerardinis","year":"2008","journal-title":"Cell Metab"},{"key":"B34","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1038\/nature08617","article-title":"Cancer-associated IDH1 mutations produce 2-hydroxyglutarate","volume":"462","author":"Dang","year":"2009","journal-title":"Nature"},{"key":"B35","doi-asserted-by":"publisher","first-page":"8788","DOI":"10.1073\/pnas.1003428107","article-title":"Mitochondrial metabolism and ROS generation are essential for Kras-mediated tumorigenicity","volume":"107","author":"Weinberg","year":"2010","journal-title":"Proc Natl Acad Sci USA"},{"key":"B36","doi-asserted-by":"publisher","first-page":"1234","DOI":"10.1002\/nbm.2794","article-title":"Metabolism of [U-13 C]glucose in human brain tumors in vivo","volume":"25","author":"Maher","year":"2012","journal-title":"NMR Biomed"},{"key":"B37","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1016\/j.cell.2017.09.019","article-title":"Lactate metabolism in human lung tumors","volume":"171","author":"Faubert","year":"2017","journal-title":"Cell"},{"key":"B38","doi-asserted-by":"publisher","first-page":"1851","DOI":"10.1182\/blood-2004-07-2947","article-title":"Molecular profiling of diffuse large B-cell lymphoma identifies robust subtypes including one characterized by host inflammatory response","volume":"105","author":"Monti","year":"2005","journal-title":"Blood"},{"key":"B39","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1016\/j.ccr.2012.08.014","article-title":"Metabolic signatures uncover distinct targets in molecular subsets of diffuse large B cell lymphoma","volume":"22","author":"Caro","year":"2012","journal-title":"Cancer Cell"},{"key":"B40","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1016\/j.ccr.2012.11.020","article-title":"PGC1alpha expression defines a subset of human melanoma tumors with increased mitochondrial capacity and resistance to oxidative stress","volume":"23","author":"Vazquez","year":"2013","journal-title":"Cancer Cell"},{"key":"B41","doi-asserted-by":"publisher","first-page":"628","DOI":"10.1038\/nature13611","article-title":"Oncogene ablation-resistant pancreatic cancer cells depend on mitochondrial function","volume":"514","author":"Viale","year":"2014","journal-title":"Nature"},{"key":"B42","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1016\/j.cell.2015.12.034","article-title":"Metabolic heterogeneity in human lung tumors","volume":"164","author":"Hensley","year":"2016","journal-title":"Cell"},{"key":"B43","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1038\/nature12122","article-title":"mTOR kinase structure, mechanism and regulation","volume":"497","author":"Yang","year":"2013","journal-title":"Nature"},{"key":"B44","doi-asserted-by":"publisher","first-page":"1194","DOI":"10.1158\/2159-8290.CD-15-0460","article-title":"PtdIns(3,4,5)P3-Dependent activation of the mTORC2 kinase complex","volume":"5","author":"Liu","year":"2015","journal-title":"Cancer Discov"},{"key":"B45","doi-asserted-by":"publisher","first-page":"1122","DOI":"10.1038\/ncb1183","article-title":"Mammalian TOR complex 2 controls the actin cytoskeleton and is rapamycin insensitive","volume":"6","author":"Jacinto","year":"2004","journal-title":"Nat Cell Biol"},{"key":"B46","doi-asserted-by":"publisher","first-page":"1296","DOI":"10.1016\/j.cub.2004.06.054","article-title":"Rictor, a novel binding partner of mTOR, defines a rapamycin-insensitive and raptor-independent pathway that regulates the cytoskeleton","volume":"14","author":"Sarbassov","year":"2004","journal-title":"Curr Biol"},{"key":"B47","doi-asserted-by":"publisher","first-page":"1098","DOI":"10.1126\/science.1106148","article-title":"Phosphorylation and regulation of Akt\/PKB by the rictor-mTOR complex","volume":"307","author":"Sarbassov","year":"2005","journal-title":"Science"},{"key":"B48","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1016\/j.cell.2007.05.058","article-title":"IKK beta suppression of TSC1 links inflammation and tumor angiogenesis via the mTOR pathway","volume":"130","author":"Lee","year":"2007","journal-title":"Cell"},{"key":"B49","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1016\/j.cell.2005.02.031","article-title":"Phosphorylation and functional inactivation of TSC2 by Erk implications for tuberous sclerosis and cancer pathogenesis","volume":"121","author":"Ma","year":"2005","journal-title":"Cell"},{"key":"B50","doi-asserted-by":"publisher","first-page":"13489","DOI":"10.1073\/pnas.0405659101","article-title":"Tumor-promoting phorbol esters and activated Ras inactivate the tuberous sclerosis tumor suppressor complex via p90 ribosomal S6 kinase","volume":"101","author":"Roux","year":"2004","journal-title":"Proc Natl Acad Sci USA"},{"key":"B51","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1016\/S0092-8674(03)00929-2","article-title":"TSC2 mediates cellular energy response to control cell growth and survival","volume":"115","author":"Inoki","year":"2003","journal-title":"Cell"},{"key":"B52","doi-asserted-by":"publisher","first-page":"2893","DOI":"10.1101\/gad.1256804","article-title":"Regulation of mTOR function in response to hypoxia by REDD1 and the TSC1\/TSC2 tumor suppressor complex","volume":"18","author":"Brugarolas","year":"2004","journal-title":"Genes Dev"},{"key":"B53","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1016\/j.molcel.2008.03.003","article-title":"AMPK phosphorylation of raptor mediates a metabolic checkpoint","volume":"30","author":"Gwinn","year":"2008","journal-title":"Mol Cell"},{"key":"B54","doi-asserted-by":"publisher","first-page":"3991","DOI":"10.1128\/MCB.00165-09","article-title":"Glycolytic flux signals to mTOR through glyceraldehyde-3-phosphate dehydrogenase-mediated regulation of Rheb","volume":"29","author":"Lee","year":"2009","journal-title":"Mol Cell Biol"},{"key":"B55","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1016\/j.tcb.2014.03.003","article-title":"Regulation of mTORC1 by amino acids","volume":"24","author":"Bar-Peled","year":"2014","journal-title":"Trends Cell Biol"},{"key":"B56","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1126\/science.aad2087","article-title":"Structural basis for leucine sensing by the Sestrin2-mTORC1 pathway","volume":"351","author":"Saxton","year":"2016","journal-title":"Science"},{"key":"B57","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1038\/nature19079","article-title":"Mechanism of arginine sensing by CASTOR1 upstream of mTORC1","volume":"536","author":"Saxton","year":"2016","journal-title":"Nature"},{"key":"B58","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1016\/j.cell.2016.02.035","article-title":"The CASTOR proteins are arginine sensors for the mTORC1 pathway","volume":"165","author":"Chantranupong","year":"2016","journal-title":"Cell"},{"key":"B59","doi-asserted-by":"publisher","first-page":"935","DOI":"10.1038\/ncb1753","article-title":"Regulation of TORC1 by Rag GTPases in nutrient response","volume":"10","author":"Kim","year":"2008","journal-title":"Nat Cell Biol"},{"key":"B60","doi-asserted-by":"publisher","first-page":"1496","DOI":"10.1126\/science.1157535","article-title":"The Rag GTPases bind raptor and mediate amino acid signaling to mTORC1","volume":"320","author":"Sancak","year":"2008","journal-title":"Science"},{"key":"B61","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1016\/j.molcel.2012.05.043","article-title":"Glutaminolysis activates Rag-mTORC1 signaling","volume":"47","author":"Dur\u00e1n","year":"2012","journal-title":"Mol Cell"},{"key":"B62","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1126\/science.1259472","article-title":"Metabolism differential regulation of mTORC1 by leucine and glutamine","volume":"347","author":"Jewell","year":"2015","journal-title":"Science"},{"key":"B63","doi-asserted-by":"publisher","first-page":"3521","DOI":"10.1182\/blood-2013-03-493163","article-title":"Inhibiting glutamine uptake represents an attractive new strategy for treating acute myeloid leukemia","volume":"122","author":"Willems","year":"2013","journal-title":"Blood"},{"key":"B64","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1126\/science.1257132","article-title":"Metabolism","volume":"347","author":"Wang","year":"2015","journal-title":"Science"},{"key":"B65","doi-asserted-by":"publisher","first-page":"7250","DOI":"10.1038\/ncomms8250","article-title":"LAPTM4b recruits the LAT1-4F2hc Leu transporter to lysosomes and promotes mTORC1 activation","volume":"6","author":"Milkereit","year":"2015","journal-title":"Nat Commun"},{"key":"B66","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1038\/nrm2672","article-title":"Molecular mechanisms of mTOR-mediated translational control","volume":"10","author":"Ma","year":"2009","journal-title":"Nat Rev Mol Cell Biol"},{"key":"B67","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1016\/j.cmet.2017.12.006","article-title":"As extracellular glutamine levels decline, asparagine becomes an essential amino acid","volume":"27","author":"Pavlova","year":"2018","journal-title":"Cell Metab"},{"key":"B68","doi-asserted-by":"publisher","first-page":"5575","DOI":"10.1128\/MCB.22.15.5575-5584.2002","article-title":"The immunosuppressant rapamycin mimics a starvation-like signal distinct from amino acid and glucose deprivation","volume":"22","author":"Peng","year":"2002","journal-title":"Mol Cell Biol"},{"key":"B69","doi-asserted-by":"publisher","first-page":"22229","DOI":"10.1073\/pnas.0912074106","article-title":"Direct control of mitochondrial function by mTOR","volume":"106","author":"Ramanathan","year":"2009","journal-title":"Proc Natl Acad Sci USA"},{"key":"B70","doi-asserted-by":"publisher","first-page":"1323","DOI":"10.1126\/science.1228792","article-title":"Stimulation of de novo pyrimidine synthesis by growth signaling through mTOR and S6K1","volume":"339","author":"Ben-Sahra","year":"2013","journal-title":"Science"},{"key":"B71","doi-asserted-by":"publisher","first-page":"728","DOI":"10.1126\/science.aad0489","article-title":"mTORC1 induces purine synthesis through control of the mitochondrial tetrahydrofolate cycle","volume":"351","author":"Ben-Sahra","year":"2016","journal-title":"Science"},{"key":"B72","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1016\/j.molcel.2010.06.022","article-title":"Activation of a metabolic gene regulatory network downstream of mTOR complex 1","volume":"39","author":"D\u00fcvel","year":"2010","journal-title":"Mol Cell"},{"key":"B73","doi-asserted-by":"publisher","first-page":"736","DOI":"10.1038\/nature06322","article-title":"mTOR controls mitochondrial oxidative function through a YY1-PGC-1alpha transcriptional complex","volume":"450","author":"Cunningham","year":"2007","journal-title":"Nature"},{"key":"B74","doi-asserted-by":"publisher","first-page":"698","DOI":"10.1016\/j.cmet.2013.10.001","article-title":"mTORC1 controls mitochondrial activity and biogenesis through 4E-BP-dependent translational regulation","volume":"18","author":"Morita","year":"2013","journal-title":"Cell Metab"},{"key":"B75","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1016\/j.cell.2011.06.034","article-title":"mTOR complex 1 regulates lipin 1 localization to control the SREBP pathway","volume":"146","author":"Peterson","year":"2011","journal-title":"Cell"},{"key":"B76","doi-asserted-by":"publisher","first-page":"2274","DOI":"10.1016\/j.cub.2014.08.007","article-title":"The mTORC1\/S6K1 pathway regulates glutamine metabolism through the eIF4B-dependent control of c-Myc translation","volume":"24","author":"Csibi","year":"2014","journal-title":"Curr Biol"},{"key":"B77","doi-asserted-by":"publisher","first-page":"840","DOI":"10.1016\/j.cell.2013.04.023","article-title":"The mTORC1 pathway stimulates glutamine metabolism and cell proliferation by repressing SIRT4","volume":"153","author":"Csibi","year":"2013","journal-title":"Cell"},{"key":"B78","doi-asserted-by":"publisher","first-page":"5347","DOI":"10.1200\/JCO.2005.13.466","article-title":"Phase II trial of single-agent temsirolimus (CCI-779) for relapsed mantle cell lymphoma","volume":"23","author":"Witzig","year":"2005","journal-title":"J Clin Oncol"},{"key":"B79","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1002\/cncr.23580","article-title":"Low-dose, single-agent temsirolimus for relapsed mantle cell lymphoma: a phase 2 trial in the North Central Cancer Treatment Group","volume":"113","author":"Ansell","year":"2008","journal-title":"Cancer"},{"key":"B80","doi-asserted-by":"publisher","first-page":"3822","DOI":"10.1200\/JCO.2008.20.7977","article-title":"Phase III study to evaluate temsirolimus compared with investigator's choice therapy for the treatment of relapsed or refractory mantle cell lymphoma","volume":"27","author":"Hess","year":"2009","journal-title":"J Clin Oncol"},{"key":"B81","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1038\/leu.2010.226","article-title":"A phase II trial of the oral mTOR inhibitor everolimus in relapsed aggressive lymphoma","volume":"25","author":"Witzig","year":"2011","journal-title":"Leukemia"},{"key":"B82","doi-asserted-by":"publisher","first-page":"1085","DOI":"10.3324\/haematol.2011.053173","article-title":"A multicenter phase II trial (SAKK 36\/06) of single-agent everolimus (RAD001) in patients with relapsed or refractory mantle cell lymphoma","volume":"97","author":"Renner","year":"2012","journal-title":"Haematologica"},{"key":"B83","doi-asserted-by":"publisher","first-page":"4740","DOI":"10.1200\/JCO.2010.29.2813","article-title":"Temsirolimus has activity in non-mantle cell non-Hodgkin's lymphoma subtypes: The University of Chicago phase II consortium","volume":"28","author":"Smith","year":"2010","journal-title":"J Clin Oncol"},{"key":"B84","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1056\/NEJMoa011795","article-title":"CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma","volume":"346","author":"Coiffier","year":"2002","journal-title":"N Engl J Med"},{"key":"B85","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1038\/35000501","article-title":"Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling","volume":"403","author":"Alizadeh","year":"2000","journal-title":"Nature"},{"key":"B86","doi-asserted-by":"publisher","first-page":"1623","DOI":"10.1038\/modpathol.2012.141","article-title":"Activity and complexes of mTOR in diffuse large B-cell lymphomas\u2013a tissue microarray study","volume":"25","author":"Sebestyen","year":"2012","journal-title":"Modern Pathol."},{"key":"B87","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1016\/j.cell.2017.09.027","article-title":"Genetic and functional drivers of diffuse large B cell lymphoma","volume":"171","author":"Reddy","year":"2017","journal-title":"Cell"},{"key":"B88","doi-asserted-by":"publisher","first-page":"2178","DOI":"10.1101\/gad.1690808","article-title":"Tumorigenic activity and therapeutic inhibition of Rheb GTPase","volume":"22","author":"Mavrakis","year":"2008","journal-title":"Genes Dev"},{"key":"B89","doi-asserted-by":"crossref","first-page":"3410","DOI":"10.1182\/blood.V92.9.3410","article-title":"PTEN gene alterations in lymphoid neoplasms","volume":"92","author":"Sakai","year":"1998","journal-title":"Blood"},{"key":"B90","doi-asserted-by":"publisher","first-page":"13520","DOI":"10.1073\/pnas.0804295105","article-title":"Molecular subtypes of diffuse large B-cell lymphoma arise by distinct genetic pathways","volume":"105","author":"Lenz","year":"2008","journal-title":"Proc Natl Acad Sci USA"},{"key":"B91","doi-asserted-by":"publisher","first-page":"12420","DOI":"10.1073\/pnas.1305656110","article-title":"PTEN loss defines a PI3K\/AKT pathway-dependent germinal center subtype of diffuse large B-cell lymphoma","volume":"110","author":"Pfeifer","year":"2013","journal-title":"Proc Natl Acad Sci USA"},{"key":"B92","doi-asserted-by":"publisher","first-page":"574","DOI":"10.1016\/j.neo.2018.03.002","article-title":"Clinical significance of PTEN deletion, mutation, and loss of PTEN expression in de Novo diffuse large B-cell lymphoma","volume":"20","author":"Wang","year":"2018","journal-title":"Neoplasia"},{"key":"B93","first-page":"14875","article-title":"Evaluation of AKT phosphorylation and PTEN loss and their correlation with the resistance of rituximab in DLBCL","volume":"8","author":"Ma","year":"2015","journal-title":"Int J Clin Exp Pathol"},{"key":"B94","doi-asserted-by":"publisher","first-page":"2368","DOI":"10.1038\/sj.leu.2404873","article-title":"PIK3CA mutations are mutually exclusive with PTEN loss in diffuse large B-cell lymphoma","volume":"21","author":"Abubaker","year":"2007","journal-title":"Leukemia"},{"key":"B95","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1097\/PDM.0b013e31815d0588","article-title":"Mutations of the PIK3CA gene in diffuse large B cell lymphoma","volume":"17","author":"Baohua","year":"2008","journal-title":"Diagn Mol Pathol"},{"key":"B96","doi-asserted-by":"publisher","first-page":"66237","DOI":"10.18632\/oncotarget.19889","article-title":"PIK3CA amplification and PTEN loss in diffused large B-cell lymphoma","volume":"8","author":"Cui","year":"2017","journal-title":"Oncotarget"},{"key":"B97","doi-asserted-by":"publisher","first-page":"7800","DOI":"10.1158\/0008-5472.CAN-04-4180","article-title":"Activation of mammalian target of rapamycin in transformed B lymphocytes is nutrient dependent but independent of Akt, mitogen-activated protein kinase\/extracellular signal-regulated kinase kinase, insulin growth factor-I, and serum","volume":"65","author":"Wlodarski","year":"2005","journal-title":"Cancer Res"},{"key":"B98","doi-asserted-by":"publisher","first-page":"9163","DOI":"10.18632\/oncotarget.7036","article-title":"Differential regulation of mTOR signaling determines sensitivity to AKT inhibition in diffuse large B cell lymphoma","volume":"7","author":"Ezell","year":"2016","journal-title":"Oncotarget"},{"key":"B99","doi-asserted-by":"publisher","first-page":"1861","DOI":"10.1084\/jem.194.12.1861","article-title":"Constitutive nuclear factor kappaB activity is required for survival of activated B cell-like diffuse large B cell lymphoma cells","volume":"194","author":"Davis","year":"2001","journal-title":"J Exp Med"},{"key":"B100","doi-asserted-by":"publisher","first-page":"1676","DOI":"10.1126\/science.1153629","article-title":"Oncogenic CARD11 mutations in human diffuse large B cell lymphoma","volume":"319","author":"Lenz","year":"2008","journal-title":"Science"},{"key":"B101","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1038\/nature07968","article-title":"Mutations of multiple genes cause deregulation of NF-kappaB in diffuse large B-cell lymphoma","volume":"459","author":"Compagno","year":"2009","journal-title":"Nature"},{"key":"B102","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1038\/nature09671","article-title":"Oncogenically active MYD88 mutations in human lymphoma","volume":"470","author":"Ngo","year":"2011","journal-title":"Nature"},{"key":"B103","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1038\/nature08638","article-title":"Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma","volume":"463","author":"Davis","year":"2010","journal-title":"Nature"},{"key":"B104","doi-asserted-by":"publisher","first-page":"4126","DOI":"10.1073\/pnas.0735266100","article-title":"Somatic hypermutation of the B cell receptor genes B29 (Igbeta, CD79b) and mb1 (Igalpha, CD79a)","volume":"100","author":"Gordon","year":"2003","journal-title":"Proc Natl Acad Sci USA"},{"key":"B105","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1016\/j.cell.2018.02.048","article-title":"B-Cell-specific diversion of glucose carbon utilization reveals a unique vulnerability in B cell malignancies","volume":"173","author":"Xiao","year":"2018","journal-title":"Cell"},{"key":"B106","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1016\/j.celrep.2013.12.027","article-title":"Genetics of follicular lymphoma transformation","volume":"6","author":"Pasqualucci","year":"2014","journal-title":"Cell Rep"},{"key":"B107","doi-asserted-by":"publisher","first-page":"3424","DOI":"10.1172\/JCI63186","article-title":"Pathogenesis of follicular lymphoma","volume":"122","author":"Kridel","year":"2012","journal-title":"J Clin Invest"},{"key":"B108","doi-asserted-by":"publisher","first-page":"4156","DOI":"10.1182\/blood-2006-05-026203","article-title":"Syk-dependent mTOR activation in follicular lymphoma cells","volume":"108","author":"Leseux","year":"2006","journal-title":"Blood"},{"key":"B109","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1182\/blood-2007-04-085092","article-title":"PKC zeta mTOR pathway: a new target for rituximab therapy in follicular lymphoma","volume":"111","author":"Leseux","year":"2008","journal-title":"Blood"},{"key":"B110","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1038\/leu.2011.248","article-title":"Involvement of the Syk-mTOR pathway in follicular lymphoma cell invasion and angiogenesis","volume":"26","author":"Fruchon","year":"2012","journal-title":"Leukemia"},{"key":"B111","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1038\/ng.3473","article-title":"Recurrent mTORC1-activating RRAGC mutations in follicular lymphoma","volume":"48","author":"Okosun","year":"2016","journal-title":"Nat Genet"},{"key":"B112","doi-asserted-by":"publisher","first-page":"1984","DOI":"10.1200\/JCO.2005.08.133","article-title":"Immunochemotherapy with rituximab and cyclophosphamide, doxorubicin, vincristine, and prednisone significantly improves response and time to treatment failure, but not long-term outcome in patients with previously untreated mantle cell lymphoma: results of a prospective randomized trial of the German Low Grade Lymphoma Study Group (GLSG)","volume":"23","author":"Lenz","year":"2005","journal-title":"J Clin Oncol"},{"key":"B113","doi-asserted-by":"publisher","first-page":"750","DOI":"10.1038\/nrc2230","article-title":"Genetic and molecular pathogenesis of mantle cell lymphoma: perspectives for new targeted therapeutics","volume":"7","author":"Jares","year":"2007","journal-title":"Nat Rev Cancer"},{"key":"B114","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1182\/blood-2010-04-189977","article-title":"Mantle cell lymphoma: biology, pathogenesis, and the molecular basis of treatment in the genomic era","volume":"117","author":"Perez-Galan","year":"2011","journal-title":"Blood"},{"key":"B115","doi-asserted-by":"publisher","first-page":"1916","DOI":"10.3109\/10428190903207548","article-title":"Exploring mammalian target of rapamycin (mTOR) inhibition for treatment of mantle cell lymphoma and other hematologic malignancies","volume":"50","author":"Coiffier","year":"2009","journal-title":"Leuk Lymphoma"},{"key":"B116","doi-asserted-by":"publisher","first-page":"1668","DOI":"10.1182\/blood-2006-04-015586","article-title":"Constitutive activation of Akt contributes to the pathogenesis and survival of mantle cell lymphoma","volume":"108","author":"Rudelius","year":"2006","journal-title":"Blood"},{"key":"B117","doi-asserted-by":"publisher","first-page":"5724","DOI":"10.1158\/1078-0432.CCR-08-3215","article-title":"Phosphatidylinositol 3'-kinase catalytic subunit alpha gene amplification contributes to the pathogenesis of mantle cell lymphoma","volume":"15","author":"Psyrri","year":"2009","journal-title":"Clin Cancer Res"},{"key":"B118","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1126\/science.273.5272.239","article-title":"Structure of the FKBP12-rapamycin complex interacting with the binding domain of human FRAP","volume":"273","author":"Choi","year":"1996","journal-title":"Science"},{"key":"B119","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1016\/j.molcel.2006.03.029","article-title":"Prolonged rapamycin treatment inhibits mTORC2 assembly and Akt\/PKB","volume":"22","author":"Sarbassov","year":"2006","journal-title":"Mol Cell"},{"key":"B120","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1016\/j.ctrv.2006.10.004","article-title":"Aspects of mTOR biology and the use of mTOR inhibitors in non-Hodgkin's lymphoma","volume":"33","author":"Costa","year":"2007","journal-title":"Cancer Treat Rev"},{"key":"B121","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1038\/sj.leu.2404471","article-title":"Antiproliferative activity of RAD001 (everolimus) as a single agent and combined with other agents in mantle cell lymphoma","volume":"21","author":"Haritunians","year":"2007","journal-title":"Leukemia"},{"key":"B122","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1111\/j.1365-2141.2006.06210.x","article-title":"Mammalian target of rapamycin inhibition induces cell cycle arrest in diffuse large B cell lymphoma (DLBCL) cells and sensitises DLBCL cells to rituximab","volume":"134","author":"Wanner","year":"2006","journal-title":"J Haematol"},{"key":"B123","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/0092-8674(86)90361-2","article-title":"The c-myc oncogene perturbs B lymphocyte development in E-mu-myc transgenic mice","volume":"47","author":"Langdon","year":"1986","journal-title":"Cell"},{"key":"B124","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.1038\/leu.2014.324","article-title":"GAPDH enhances the aggressiveness and the vascularization of non-Hodgkin's B lymphomas via NF-kappaB-dependent induction of HIF-1alpha","volume":"29","author":"Chiche","year":"2015","journal-title":"Leukemia"},{"key":"B125","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1158\/2159-8290.CD-12-0404","article-title":"The mTORC1 inhibitor everolimus prevents and treats Emu-Myc lymphoma by restoring oncogene-induced senescence","volume":"3","author":"Wall","year":"2012","journal-title":"Cancer Discov"},{"key":"B126","doi-asserted-by":"publisher","first-page":"1190","DOI":"10.1038\/nm.3940","article-title":"Disruption of KMT2D perturbs germinal center B cell development and promotes lymphomagenesis","volume":"21","author":"Zhang","year":"2015","journal-title":"Nat Med"},{"key":"B127","doi-asserted-by":"publisher","first-page":"1199","DOI":"10.1038\/nm.3943","article-title":"The histone lysine methyltransferase KMT2D sustains a gene expression program that represses B cell lymphoma development","volume":"21","author":"Ortega-Molina","year":"2015","journal-title":"Nat Med"},{"key":"B128","doi-asserted-by":"publisher","first-page":"4212","DOI":"10.1158\/1078-0432.CCR-16-2703","article-title":"B-Cell Lymphoma Patient-derived xenograft models enable drug discovery and are a platform for personalized therapy","volume":"23","author":"Zhang","year":"2017","journal-title":"Clin Cancer Res"},{"key":"B129","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1056\/NEJMoa063564","article-title":"Sirolimus for angiomyolipoma in tuberous sclerosis complex or lymphangioleiomyomatosis","volume":"358","author":"Bissler","year":"2008","journal-title":"N Engl J Med"},{"key":"B130","doi-asserted-by":"publisher","first-page":"1151","DOI":"10.3109\/10428194.2013.823492","article-title":"Combination of rituximab and mammalian target of rapamycin inhibitor everolimus (RAD001) in diffuse large B-cell lymphoma","volume":"55","author":"Xu","year":"2014","journal-title":"Leuk Lymphoma"},{"key":"B131","doi-asserted-by":"publisher","first-page":"755","DOI":"10.3324\/haematol.2016.159160","article-title":"Inhibition of 4EBP phosphorylation mediates the cytotoxic effect of mechanistic target of rapamycin kinase inhibitors in aggressive B-cell lymphomas","volume":"102","author":"Bi","year":"2017","journal-title":"Haematologica"},{"key":"B132","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1517\/14740338.2013.752814","article-title":"Adverse events associated with mTOR inhibitors","volume":"12","author":"Pallet","year":"2013","journal-title":"Expert Opin Drug Saf"},{"key":"B133","doi-asserted-by":"publisher","first-page":"1213","DOI":"10.1111\/bcp.12888","article-title":"Targeting mTOR for the treatment of B cell malignancies","volume":"82","author":"Lee","year":"2016","journal-title":"Br J Clin Pharmacol"},{"key":"B134","doi-asserted-by":"publisher","first-page":"17414","DOI":"10.1073\/pnas.0809136105","article-title":"Rapamycin differentially inhibits S6Ks and 4E-BP1 to mediate cell-type-specific repression of mRNA translation","volume":"105","author":"Choo","year":"2008","journal-title":"Proc Natl Acad Sci USA"},{"key":"B135","doi-asserted-by":"publisher","first-page":"1236566","DOI":"10.1126\/science.1236566","article-title":"mTORC1 phosphorylation sites encode their sensitivity to starvation and rapamycin","volume":"341","author":"Kang","year":"2013","journal-title":"Science"},{"key":"B136","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1016\/S1470-2045(11)70062-6","article-title":"Temsirolimus and rituximab in patients with relapsed or refractory mantle cell lymphoma: a phase 2 study","volume":"12","author":"Ansell","year":"2011","journal-title":"Lancet Oncol"},{"key":"B137","doi-asserted-by":"publisher","first-page":"615","DOI":"10.3324\/haematol.2012.075184","article-title":"Everolimus in combination with rituximab induces complete responses in heavily pretreated diffuse large B-cell lymphoma","volume":"98","author":"Barnes","year":"2013","journal-title":"Haematologica"},{"key":"B138","doi-asserted-by":"publisher","first-page":"7117","DOI":"10.1158\/0008-5472.CAN-03-3500","article-title":"Inhibition of the Raf-MEK1\/2-ERK1\/2 signaling pathway, Bcl-xL down-regulation, and chemosensitization of non-Hodgkin's lymphoma B cells by Rituximab","volume":"64","author":"Jazirehi","year":"2004","journal-title":"Cancer Res"},{"key":"B139","first-page":"5137","article-title":"Rituximab inactivates signal transducer and activation of transcription 3 (STAT3) activity in B-non-Hodgkin's lymphoma through inhibition of the interleukin 10 autocrine\/paracrine loop and results in down-regulation of Bcl-2 and sensitization to cytotoxic drugs","volume":"61","author":"Alas","year":"2001","journal-title":"Cancer Res"},{"key":"B140","doi-asserted-by":"publisher","first-page":"1038","DOI":"10.1182\/blood.V99.3.1038","article-title":"The mechanism of tumor cell clearance by rituximab in vivo in patients with B-cell chronic lymphocytic leukemia: evidence of caspase activation and apoptosis induction","volume":"99","author":"Byrd","year":"2002","journal-title":"Blood"},{"key":"B141","doi-asserted-by":"publisher","first-page":"985","DOI":"10.1182\/blood-2009-08-237537","article-title":"Rituximab inhibits B-cell receptor signaling","volume":"115","author":"Kheirallah","year":"2010","journal-title":"Blood"},{"key":"B142","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1200\/JCO.2000.18.2.317","article-title":"European phase II study of rituximab (chimeric anti-CD20 monoclonal antibody) for patients with newly diagnosed mantle-cell lymphoma and previously treated mantle-cell lymphoma, immunocytoma, and small B-cell lymphocytic lymphoma","volume":"18","author":"Foran","year":"2000","journal-title":"J Clin Oncol"},{"key":"B143","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1200\/JCO.2005.04.164","article-title":"Effect of single-agent rituximab given at the standard schedule or as prolonged treatment in patients with mantle cell lymphoma: a study of the Swiss Group for Clinical Cancer Research (SAKK)","volume":"234","author":"Ghielmini","year":"2005","journal-title":"J Clin Oncol"},{"key":"B144","first-page":"1927","article-title":"Rituximab (anti-CD20 monoclonal antibody) for the treatment of patients with relapsing or refractory aggressive lymphoma: a multicenter phase II study","volume":"92","author":"Coiffier","year":"1998","journal-title":"Blood"},{"key":"B145","doi-asserted-by":"publisher","first-page":"e309","DOI":"10.1016\/S2352-3026(16)30040-0","article-title":"Everolimus combined with R-CHOP-21 for new, untreated, diffuse large B-cell lymphoma (NCCTG 1085 [Alliance]): safety and efficacy results of a phase 1 and feasibility trial","volume":"3","author":"Johnston","year":"2016","journal-title":"Lancet Haematol"},{"key":"B146","doi-asserted-by":"publisher","first-page":"2349","DOI":"10.1073\/pnas.1311846111","article-title":"High-throughput combinatorial screening identifies drugs that cooperate with ibrutinib to kill activated B-cell-like diffuse large B-cell lymphoma cells","volume":"111","author":"Mathews Griner","year":"2014","journal-title":"Proc Natl Acad Sci USA"},{"key":"B147","doi-asserted-by":"publisher","first-page":"4990","DOI":"10.18632\/oncotarget.2071","article-title":"Synergistic induction of apoptosis by combination of BTK and dual mTORC1\/2 inhibitors in diffuse large B cell lymphoma","volume":"5","author":"Ezell","year":"2014","journal-title":"Oncotarget"},{"key":"B148","doi-asserted-by":"publisher","first-page":"2926","DOI":"10.1182\/blood-2009-05-220889","article-title":"Inhibition of histone deacetylase overcomes rapamycin-mediated resistance in diffuse large B-cell lymphoma by inhibiting Akt signaling through mTORC2","volume":"114","author":"Gupta","year":"2009","journal-title":"Blood"},{"key":"B149","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1016\/j.exphem.2007.12.008","article-title":"Temsirolimus downregulates p21 without altering cyclin D1 expression and induces autophagy and synergizes with vorinostat in mantle cell lymphoma","volume":"36","author":"Yazbeck","year":"2008","journal-title":"Exp Hematol"},{"key":"B150","doi-asserted-by":"publisher","first-page":"6882","DOI":"10.1158\/1078-0432.CCR-13-1906","article-title":"Phase I study of panobinostat plus everolimus in patients with relapsed or refractory lymphoma","volume":"19","author":"Oki","year":"2013","journal-title":"Clin Cancer Res"},{"key":"B151","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1186\/1471-2407-13-308","article-title":"A phase I\/II trial to evaluate the safety, feasibility and activity of salvage therapy consisting of the mTOR inhibitor Temsirolimus added to standard therapy of Rituximab and DHAP for the treatment of patients with relapsed or refractory diffuse large cell B-Cell lymphoma - the STORM trial","volume":"13","author":"Witzens-Harig","year":"2013","journal-title":"BMC Cancer"},{"key":"B152","doi-asserted-by":"publisher","first-page":"2020","DOI":"10.1182\/blood-2008-02-137141","article-title":"mTOR inhibitors are synergistic with methotrexate: an effective combination to treat acute lymphoblastic leukemia","volume":"112","author":"Teachey","year":"2008","journal-title":"Blood"},{"key":"B153","doi-asserted-by":"publisher","first-page":"716","DOI":"10.1158\/2159-8290.CD-16-0441","article-title":"Chemotherapy-resistant human acute myeloid leukemia cells are not enriched for leukemic stem cells but require oxidative metabolism","volume":"7","author":"Farge","year":"2017","journal-title":"Cancer Discov"},{"key":"B154","doi-asserted-by":"publisher","first-page":"e188","DOI":"10.1038\/oncsis.2015.46","article-title":"Energy disruptors: rising stars in anticancer therapy?","volume":"5","author":"Bost","year":"2016","journal-title":"Oncogenesis"},{"key":"B155","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1042\/0264-6021:3480607","article-title":"Evidence that metformin exerts its anti-diabetic effects through inhibition of complex 1 of the mitochondrial respiratory chain","volume":"348","author":"Owen","year":"2000","journal-title":"Biochem J"},{"key":"B156","doi-asserted-by":"publisher","first-page":"1167","DOI":"10.1172\/JCI13505","article-title":"Role of AMP-activated protein kinase in mechanism of metformin action","volume":"108","author":"Zhou","year":"2001","journal-title":"J Clin Invest"},{"key":"B157","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1074\/jbc.275.1.223","article-title":"Dimethylbiguanide inhibits cell respiration via an indirect effect targeted on the respiratory chain complex I","volume":"275","author":"El-Mir","year":"2000","journal-title":"J Biol Chem"},{"key":"B158","doi-asserted-by":"publisher","first-page":"10269","DOI":"10.1158\/0008-5472.CAN-06-1500","article-title":"Metformin is an AMP kinase-dependent growth inhibitor for breast cancer cells","volume":"66","author":"Zakikhani","year":"2006","journal-title":"Cancer Res"},{"key":"B159","doi-asserted-by":"publisher","first-page":"4366","DOI":"10.1158\/0008-5472.CAN-10-1769","article-title":"Metformin, independent of AMPK, induces mTOR inhibition and cell-cycle arrest through REDD1","volume":"71","author":"Ben Sahra","year":"2011","journal-title":"Cancer Res"},{"key":"B160","doi-asserted-by":"publisher","first-page":"e02242","DOI":"10.7554\/eLife.02242","article-title":"Metformin inhibits mitochondrial complex I of cancer cells to reduce tumorigenesis","volume":"3","author":"Wheaton","year":"2014","journal-title":"Elife"},{"key":"B161","doi-asserted-by":"publisher","first-page":"21166","DOI":"10.18632\/oncotarget.24989","article-title":"Metabolic changes associated with metformin potentiates Bcl-2 inhibitor, Venetoclax, and CDK9 inhibitor, BAY1143572 and reduces viability of lymphoma cells","volume":"9","author":"Chukkapalli","year":"2018","journal-title":"Oncotarget"},{"key":"B162","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1016\/j.cmet.2016.12.009","article-title":"Metformin inhibits hepatic mTORC1 signaling via dose-dependent mechanisms involving AMPK and the TSC complex","volume":"25","author":"Howell","year":"2017","journal-title":"Cell Metab"},{"key":"B163","doi-asserted-by":"publisher","first-page":"10804","DOI":"10.1158\/0008-5472.CAN-07-2310","article-title":"Metformin inhibits mammalian target of rapamycin-dependent translation initiation in breast cancer cells","volume":"67","author":"Dowling","year":"2007","journal-title":"Cancer Res"},{"key":"B164","doi-asserted-by":"publisher","first-page":"e275","DOI":"10.1038\/cddis.2012.13","article-title":"Therapeutic metformin\/AMPK activation blocked lymphoma cell growth via inhibition of mTOR pathway and induction of autophagy","volume":"3","author":"Shi","year":"2012","journal-title":"Cell Death Dis"},{"key":"B165","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmet.2018.09.001","article-title":"Translational and HIF-1alpha-dependent metabolic reprogramming underpin metabolic plasticity and responses to kinase inhibitors and biguanides","author":"Hulea","year":"2018","journal-title":"Cell Metab"},{"key":"B166","doi-asserted-by":"publisher","first-page":"1130","DOI":"10.1080\/10428194.2016.1239822","article-title":"Clinical impact of metformin in diabetic diffuse large B-cell lymphoma patients: a case-control study","volume":"58","author":"Alkhatib","year":"2016","journal-title":"Leuk Lymphoma"},{"key":"B167","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1016\/j.ccell.2016.02.018","article-title":"mTORC1-Dependent Metabolic Reprogramming Underlies Escape from Glycolysis Addiction in Cancer Cells","volume":"29","author":"Pusapati","year":"2016","journal-title":"Cancer Cell"},{"key":"B168","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1016\/j.ccr.2006.04.023","article-title":"Attenuation of LDH-A expression uncovers a link between glycolysis, mitochondrial physiology, and tumor maintenance","volume":"9","author":"Fantin","year":"2006","journal-title":"Cancer Cell"},{"key":"B169","doi-asserted-by":"publisher","first-page":"2037","DOI":"10.1073\/pnas.0914433107","article-title":"Inhibition of lactate dehydrogenase A induces oxidative stress and inhibits tumor progression","volume":"107","author":"Le","year":"2010","journal-title":"Proc Natl Acad Sci USA"},{"key":"B170","doi-asserted-by":"publisher","first-page":"16663","DOI":"10.1073\/pnas.1106123108","article-title":"CD147 subunit of lactate\/H+ symporters MCT1 and hypoxia-inducible MCT4 is critical for energetics and growth of glycolytic tumors","volume":"108","author":"Le Floch","year":"2011","journal-title":"Proc Natl Acad Sci USA"},{"key":"B171","doi-asserted-by":"publisher","first-page":"1591","DOI":"10.1172\/JCI78239","article-title":"Compensatory glutamine metabolism promotes glioblastoma resistance to mTOR inhibitor treatment","volume":"125","author":"Tanaka","year":"2015","journal-title":"J Clin Invest"},{"key":"B172","doi-asserted-by":"publisher","first-page":"890","DOI":"10.1158\/1535-7163.MCT-13-0870","article-title":"Antitumor activity of the glutaminase inhibitor CB-839 in triple-negative breast cancer","volume":"13","author":"Gross","year":"2014","journal-title":"Mol Cancer Ther"},{"key":"B173","doi-asserted-by":"publisher","first-page":"1346","DOI":"10.1182\/blood-2015-01-621870","article-title":"Targeting glutaminolysis has antileukemic activity in acute myeloid leukemia and synergizes with BCL-2 inhibition","volume":"126","author":"Jacque","year":"2015","journal-title":"Blood"},{"key":"B174","doi-asserted-by":"publisher","first-page":"6539","DOI":"10.1073\/pnas.1507228112","article-title":"MYC oncogene overexpression drives renal cell carcinoma in a mouse model through glutamine metabolism","volume":"112","author":"Shroff","year":"2015","journal-title":"Proc Natl Acad Sci USA"},{"key":"B175","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1126\/science.1226344","article-title":"Genome sequencing identifies a basis for everolimus sensitivity","volume":"338","author":"Iyer","year":"2012","journal-title":"Science"},{"key":"B176","doi-asserted-by":"publisher","first-page":"546","DOI":"10.1158\/2159-8290.CD-13-0353","article-title":"Activating mTOR mutations in a patient with an extraordinary response on a phase I trial of everolimus and pazopanib","volume":"4","author":"Wagle","year":"2013","journal-title":"Cancer Discov"},{"key":"B177","doi-asserted-by":"publisher","first-page":"554","DOI":"10.1158\/2159-8290.CD-13-0929","article-title":"A diverse array of cancer-associated MTOR mutations are hyperactivating and can predict rapamycin sensitivity","volume":"4","author":"Grabiner","year":"2014","journal-title":"Cancer Discov"},{"key":"B178","first-page":"907","article-title":"Methods to identify molecular expression of mTOR pathway: a rationale approach to stratify patients affected by clear cell renal cell carcinoma for more likely response to mTOR inhibitors","volume":"4","author":"Fiorini","year":"2014","journal-title":"Am J Cancer Res"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fonc.2018.00556\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,7]],"date-time":"2022-09-07T13:18:06Z","timestamp":1662556686000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fonc.2018.00556\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,12,4]]},"references-count":178,"alternative-id":["10.3389\/fonc.2018.00556"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2018.00556","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,12,4]]},"article-number":"556"}}